US 12,465,631 B2
Reducing immunogenicity to pegloticase
Jeffrey D. Kent, Deerfield, IL (US); Brian Lamoreaux, Deerfield, IL (US); John Botson, Anchorage, AK (US); and Jeff Peterson, Kirkland, WA (US)
Assigned to Horizon Therapeutics USA, Inc., Deerfield, IL (US)
Filed by Horizon Therapeutics USA, Inc., Deerfield, IL (US)
Filed on Sep. 28, 2022, as Appl. No. 17/955,437.
Application 17/955,437 is a continuation of application No. 16/777,646, filed on Jan. 30, 2020, abandoned.
Claims priority of provisional application 62/903,570, filed on Sep. 20, 2019.
Claims priority of provisional application 62/855,519, filed on May 31, 2019.
Claims priority of provisional application 62/798,786, filed on Jan. 30, 2019.
Prior Publication US 2023/0173035 A1, Jun. 8, 2023
Int. Cl. A61K 38/44 (2006.01); A61K 31/519 (2006.01); A61K 47/34 (2017.01); A61P 19/06 (2006.01)
CPC A61K 38/44 (2013.01) [A61K 31/519 (2013.01); A61K 47/34 (2013.01); A61P 19/06 (2018.01)] 18 Claims
 
1. A method of treating chronic refractory gout in a patient comprising:
administering a uricase protein to the patient,
wherein 8 mg of uricase protein is administered intravenously every 2 weeks, and
administering methotrexate (MTX) to the patient,
wherein 15 mg of MTX is administered orally per week to the patient;
wherein a serum uric acid (SUA) level of the patient is measured before each infusion; and
wherein treatment is discontinued if the SUA level of the patient is above 6 mg/dl.